Quick Answer
Cardiff Oncology, Inc. reported Total Revenue of $593.0 thousand for fiscal year 2025.
Cardiff Oncology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $593.0K -13.2% |
$683.0K +40.0% |
$488.0K +26.4% |
$386.0K +7.5% |
$359.0K -1.9% |
$366.0K +49.6% |
| Revenue (ASC 606) | $593.0K -13.2% |
$683.0K +40.0% |
$488.0K +26.4% |
$386.0K +7.5% |
$359.0K -1.9% |
$366.0K |
| Net Income | -$45.85M -0.9% |
-$45.43M -9.6% |
-$41.44M -7.1% |
-$38.70M -36.8% |
-$28.29M -46.5% |
-$19.31M -17.6% |
| Diluted EPS | -$0.69 +27.4% |
-$0.95 -2.2% |
-$0.93 -4.5% |
-$0.89 -21.9% |
-$0.73 +32.4% |
-$1.08 |
| Total Assets | $61.88M -36.3% |
$97.19M +19.1% |
$81.64M -29.7% |
$116.19M -22.3% |
$149.54M +11.0% |
$134.73M +929.5% |
| Cash and Equivalents | $17.47M -66.1% |
$51.47M +137.7% |
$21.66M +32.5% |
$16.35M +36.9% |
$11.94M -90.9% |
$130.98M +1184.7% |
| Stockholders Equity | $45.39M -45.3% |
$82.95M +18.9% |
$69.74M -34.4% |
$106.34M -24.3% |
$140.42M +9.6% |
$128.16M +1652.7% |
| Operating Income | -$48.96M -0.6% |
-$48.65M -7.1% |
-$45.41M -13.8% |
-$39.90M -38.3% |
-$28.86M -51.2% |
-$19.09M -14.4% |
| Shares Outstanding | 68.31M +2.7% |
66.52M +48.9% |
44.68M +0.0% |
44.68M +6.5% |
41.96M +14.1% |
36.78M +328.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $120.0K | -27.3% | -0.8% |
| Revenue (ASC 606) | September 30, 2025 | $120.0K | -27.3% | -0.8% |
| Net Income | September 30, 2025 | -$11.26M | +5.0% | +19.3% |
| Diluted EPS | September 30, 2025 | -$0.17 | +32.0% | +19.0% |
| Total Assets | September 30, 2025 | $63.78M | +1.4% | -15.8% |
| Cash and Equivalents | September 30, 2025 | $10.13M | -22.3% | -6.0% |
| Stockholders Equity | September 30, 2025 | $48.79M | -1.2% | -16.7% |
| Operating Income | September 30, 2025 | -$11.97M | +5.0% | +19.0% |
| Shares Outstanding | September 30, 2025 | 67.09M | +37.7% | +0.9% |
- Cardiff Oncology, Inc. reported Total Revenue of $593.0 thousand for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -13.2% in Total Revenue compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Revenue (ASC 606) of $593.0 thousand for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -13.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Net Income of -$45.85 million for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -0.9% in Net Income compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Diluted EPS of $0.69 per share (loss) for fiscal year 2025.
- Cardiff Oncology, Inc. showed an increase of +27.4% in Diluted EPS compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Total Assets of $61.88 million for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -36.3% in Total Assets compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Cash and Equivalents of $17.47 million for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -66.1% in Cash and Equivalents compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Stockholders Equity of $45.39 million for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -45.3% in Stockholders Equity compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Operating Income of -$48.96 million for fiscal year 2025.
- Cardiff Oncology, Inc. showed a decrease of -0.6% in Operating Income compared to the prior fiscal year.
- Cardiff Oncology, Inc. reported Shares Outstanding of 68.31 million shares for fiscal year 2025.
- Cardiff Oncology, Inc. showed an increase of +2.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: